← FDA DRUG APPROVALS

FDA ANDA · ANDA065252

CEFTRIAXONE

Sponsor: FRESENIUS KABI USA

APPLICATION
ANDA065252
TYPE
ANDA
ORIGINAL APPROVAL
2006-02-15
LATEST ACTION
2009-05-07
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Discontinued

Products

CEFTRIAXONEDiscontinued
CEFTRIAXONE SODIUM EQ 10GM BASE/VIAL · INJECTABLE · INJECTION

Approval history

2009-05-07Labeling · Supplement 3AP
2009-01-15Labeling · Supplement 2AP
2006-02-15OriginalOther Important Information from FDAAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →